Drug Profile

NIB 103

Alternative Names: NIB-103; TAK-103

Latest Information Update: 10 Sep 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Yamaguchi University
Developer Noile-Immune Biotech; Takeda
Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

10 Sep 2026 Phase-I clinical trials in Ovarian cancer (IV), prior to September 2026 (Noile-Immune Biotech pipeline, September 2026)
10 Sep 2026 Phase-I clinical trials in Triple-negative-breast-cancer (IV), prior to September 2026 (Noile-Immune Biotech pipeline, September 2026)
02 Jul 2025 NIB 103 is still in phase-I clinical trials for Solid tumours (Late-stage disease, Metastatic disease) in Japan (IV) (NOile Immune Biotech pipeline, July 2025)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com